Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$34.42−1.49 (-4.15%)
Close on Nov 18, 2026Market cap $1.18BP/E –Yield –
Nektar Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Nektar Therapeutics's operating income for the twelve months ending Dec 31, 2025 was -$140.10M. For fiscal 2025 it was -$140.10M. The highest annual figure on record is $687.93M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$140.10M | – |
| FY2024 | Dec 31, 2024 | -$105.20M | – |
| FY2023 | Dec 31, 2023 | -$263.68M | – |
| FY2022 | Dec 31, 2022 | -$376.17M | – |
| FY2021 | Dec 31, 2021 | -$446.10M | – |
| FY2020 | Dec 31, 2020 | -$425.11M | – |
| FY2019 | Dec 31, 2019 | -$440.04M | -164.0% |
| FY2018 | Dec 31, 2018 | $687.93M | – |
| FY2017 | Dec 31, 2017 | -$59.64M | – |
| FY2016 | Dec 31, 2016 | -$112.86M | – |
| FY2015 | Dec 31, 2015 | -$29.37M | – |
| FY2014 | Dec 31, 2014 | -$16.49M | – |
| FY2013 | Dec 31, 2013 | -$120.13M | – |
| FY2012 | Dec 31, 2012 | -$141.20M | – |
| FY2011 | Dec 31, 2011 | -$123.94M | – |
| FY2010 | Dec 31, 2010 | -$28.26M | – |
| FY2009 | Dec 31, 2009 | -$95.13M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$27.67M | -292.8% |
| Q3 FY2025 | Sep 30, 2025 | -$31.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.54M | – |
| Q4 FY2024 | Dec 31, 2024 | $14.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$49.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$35.43M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$44.86M | – |
| Q2 FY2023 | Jun 30, 2023 | -$50.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$134.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$52.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$152.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -$116.56M | – |
| Q4 FY2021 | Dec 31, 2021 | -$112.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$113.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$110.21M | – |
| Q1 FY2021 | Mar 31, 2021 | -$109.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$110.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$103.05M | – |
| Q2 FY2020 | Jun 30, 2020 | -$77.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$133.63M | – |
| Q4 FY2019 | Dec 31, 2019 | -$109.64M | – |
| Q3 FY2019 | Sep 30, 2019 | -$98.74M | – |
| Q2 FY2019 | Jun 30, 2019 | -$110.97M | -111.4% |
| Q1 FY2019 | Mar 31, 2019 | -$120.69M | – |
| Q4 FY2018 | Dec 31, 2018 | -$100.30M | – |
| Q3 FY2018 | Sep 30, 2018 | -$98.63M | -242.0% |
| Q2 FY2018 | Jun 30, 2018 | $973.60M | – |
| Q1 FY2018 | Mar 31, 2018 | -$86.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.03M | – |
| Q3 FY2017 | Sep 30, 2017 | $69.49M | – |
| Q2 FY2017 | Jun 30, 2017 | -$50.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$54.44M | – |
| Q4 FY2016 | Dec 31, 2016 | -$32.15M | – |
| Q3 FY2016 | Sep 30, 2016 | -$32.90M | – |
| Q2 FY2016 | Jun 30, 2016 | -$38.33M | – |
See a number that looks wrong?